Dry Powder Inhaler Formulation
The DOI matches its OpenAlex record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
A drug product combines pharmacologic activity with pharmaceutical properties. Desirable performance characteristics are physical and chemical stability, ease of processing, accurate and reproducible delivery to the target organ, and availability at the site of action. For the dry powder inhaler (DPI), these goals can be met with a suitable powder formulation, an efficient metering system, and a carefully selected device. This review focuses on the DPI formulation and development process. Most DPI formulations consist of micronized drug blended with larger carrier particles, which enhance flow, reduce aggregation, and aid in dispersion. A combination of intrinsic physicochemical properties, particle size, shape, surface area, and morphology affects the forces of interaction and aerodynamic properties, which in turn determine fluidization, dispersion, delivery to the lungs, and deposition in the peripheral airways. When a DPI is actuated, the formulation is fluidized and enters the patient's airways. Under the influence of inspiratory airflow, the drug particles separate from the carrier particles and are carried deep into the lungs, while the larger carrier particles impact on the oropharyngeal surfaces and are cleared. If the cohesive forces acting on the powder are too strong, the shear of the airflow may not be sufficient to separate the drug from the carrier particles, which results in low deposition efficiency. Advances in understanding of aerosol and solid state physics and interfacial chemistry are moving formulation development from an empirical activity to a fundamental scientific foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adsorption of Gases in Multimolecular Layers
Brunauer, S., Emmett, P. H., & Teller, E. (1938) · Journal of the American Chemical Society · doi:10.1021/ja01269a023 · Cited by 28,156
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Intermolecular and Surface Forces
(2011) · Intermolecular and Surface Forces · doi:10.1016/b978-0-12-391927-4.10024-6 · Cited by 16,923
Binnig, G., Quate, C. F., & Gerber, C. (1986) · Physical Review Letters · doi:10.1103/physrevlett.56.930 · Cited by 14,762
Perry's chemical engineers' handbook
(2008) · Choice Reviews Online · doi:10.5860/choice.45-4393 · Cited by 10,121
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
From Molecules to Crystal Engineering: Supramolecular Isomerism and Polymorphism in Network Solids
Moulton, B., & Zaworotko, M. J. (2001) · Chemical Reviews · doi:10.1021/cr9900432 · Cited by 6,395
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Handbook of Pharmaceutical Excipients
Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (1994) · Cited by 3,493
Multiphase Flows with Droplets and Particles
Crowe, C. T., Schwarzkopf, J. D., Sommerfeld, M., & Tsuji, Y. (2011) · doi:10.1201/b11103 · Cited by 3,076
Cited by
Formulation strategy and use of excipients in pulmonary drug delivery
Pilcer, G., & Amighi, K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.017 · Cited by 791
Non-invasive delivery strategies for biologics
Anselmo, A. C., Gokarn, Y., & Mitragotri, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.183 · Cited by 665
Formulation, stabilisation and encapsulation of bacteriophage for phage therapy
Malik, D. J., Sokolov, I. J., Vinner, G. K., Mancuso, F., Cinquerrui, S., Vladisavljevic, G. T., Clokie, M. R. J., Garton, N. J., Stapley, A. G. F., & Kirpichnikova, A. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.05.014 · Cited by 594
An overview of clinical and commercial impact of drug delivery systems
Anselmo, A. C., & Mitragotri, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.053 · Cited by 520
Technological and practical challenges of dry powder inhalers and formulations
Hoppentocht, M., Hagedoorn, P., Frijlink, H. W., & de Boer, A. H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.04.004 · Cited by 303
Dry powder inhalers (DPIs)—A review of device reliability and innovation
Islam, N., & Gladki, E. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.044 · Cited by 298
Mangal, S., Gao, W., Li, T., & Zhou, Q. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.34 · Cited by 288
Targeted Drug-Aerosol Delivery in the Human Respiratory System
Kleinstreuer, C., Zhang, Z., & Donohue, J. F. (2008) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.10.061807.160544 · Cited by 267
Oxidation increases mucin polymer cross-links to stiffen airway mucus gels
Yuan, S., Hollinger, M., Lachowicz-Scroggins, M. E., Kerr, S. C., Dunican, E. M., Daniel, B. M., Ghosh, S., Erzurum, S. C., Willard, B., Hazen, S. L., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010525 · Cited by 262
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
Andrade, F., Rafael, D., Videira, M., Ferreira, D., Sosnik, A., & Sarmento, B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.020 · Cited by 245
The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy
Mortensen, N. P., Durham, P., & Hickey, A. J. (2014) · Journal of Microencapsulation · doi:10.3109/02652048.2014.932029 · Cited by 52
Self-citation
Metadata
- Authors
- Telko, M. J., & Hickey, A. J.
- Venue
- Respiratory Care
- Publisher
- American Association for Respiratory Care
- Published
- 2005-09-01
- Volume
- 50
- Issue
- 9
- Pages
- 1209-1227
- ISSN
- 0020-1324 (ISSN-L)
- OpenAlex
- W1869177231
- Cited by
- 498
- References
- 72
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.